SEMAGLUTIDE IN THE TREATMENT OF OBESITY- A NEW LOOK AT AN EFFECTIVE PHARMACOLOGICAL TOOL IN THE FIGHT AGAINST EXCESSIVE BODY WEIGHT

Monika Rogowska; Paulina Lewaśkiewicz; Karolina Wojdat-Krupa; Paweł Babiński; Filip Lachowski

doi:10.31435/ijitss.1(49).2026.5096

Authors

Monika Rogowska Independent Public Hospital No. 4 in Lublin, Lublin, Poland https://orcid.org/0000-0002-9617-7307
Paulina Lewaśkiewicz University of Pavol Jozef Safarik, Košice, Slovakia https://orcid.org/0009-0008-2361-4917
Karolina Wojdat-Krupa Szpital Morski im. PCK, Gdynia, Poland https://orcid.org/0009-0003-0942-8273
Paweł Babiński Szpital Morski im. PCK, Gdynia, Poland https://orcid.org/0009-0000-8597-8910
Filip Lachowski PCK Maritime Hospital, Gdynia, Poland https://orcid.org/0000-0001-5451-4996

DOI:

https://doi.org/10.31435/ijitss.1(49).2026.5096

Keywords:

Semaglutide, Glucagon-Like Peptide-1, Obesity Treatment, Weight Loss

Abstract

Obesity is a chronic and progressive disease, the prevalence of which continues to rise worldwide, leading to a worsening quality of life, increased incidence of other diseases, and mortality. Treating obesity poses many challenges in daily clinical practice, therefore requiring a comprehensive medical approach that involves not only lifestyle changes but also pharmacotherapy and the use of bariatric surgery methods. Due to the ongoing exploration of obesity-related issues, therapy with semaglutide, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, has gained popularity, recently approved for treating obesity. Numerous clinical studies and observations have demonstrated that semaglutide has the most significant impact on weight loss among all drugs used in obesity therapy, accompanied by improvements in quality of life and cardiovascular risk factors.

The aim of this article is to present the current state of knowledge regarding the use of semaglutide in obesity therapy, its safety, and its correlation with other obesity treatment methods.

In this article, we used English databases such as PubMed, Google Scholar and Medline. We selected articles based on keywords such as semaglutide, glucagon-like peptide –1, obesity treatment, weight loss.

References

Shamseddeen, H., Getty, J. Z., Hamdallah, I. N., & Ali, M. R. (2011). Epidemiology and economic impact of obesity and type 2 diabetes. Surgical Clinics of North America, 91(6), 1163–vii. https://doi.org/10.1016/j.suc.2011.08.001

Apovian, C. M. (2016). Obesity: Definition, comorbidities, causes, and burden. The American Journal of Managed Care, 22(7 Suppl.), S176–S185.

World Health Organization. (n.d.). Obesity. Accessed February 19, 2023.

Westbury, S., Oyebode, O., van Rens, T., & Barber, T. M. (2023). Obesity stigma: Causes, consequences, and potential solutions. Current Obesity Reports, 12(1), 10–23. https://doi.org/10.1007/s13679-023-00495-3

Endalifer, M. L., & Diress, G. (2020). Epidemiology, predisposing factors, biomarkers, and prevention mechanism of obesity: A systematic review. Journal of Obesity, 2020, Article 6134362. https://doi.org/10.1155/2020/6134362

Steenblock, C., Hassanein, M., Khan, E. G., Yaman, M., Kamel, M., Barbir, M., Lorke, D. E., Everett, D., Bejtullah, S., Lohmann, T., Lindner, U., Tahirukaj, E., Jirjees, F. J., Soliman, S. S. M., Quitter, F., & Bornstein, S. R. (2022). Obesity and COVID-19: What are the consequences? Hormone and Metabolic Research, 54(8), 496–502. https://doi.org/10.1055/a-1878-9757

Zatońska, K., Psikus, P., Basiak-Rasała, A., et al. (2021). Obesity and chosen non-communicable diseases in PURE Poland cohort study. International Journal of Environmental Research and Public Health, 18(5), Article 2701. https://doi.org/10.3390/ijerph18052701

Powell-Wiley, T. M., Poirier, P., Burke, L. E., et al. (2021). Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 143(21), e984–e1010. https://doi.org/10.1161/CIR.0000000000000973

Lau, J., Bloch, P., Schäffer, L., et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726

Pyke, C., Heller, R. S., Kirk, R. K., et al. (2014). GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155(4), 1280–1290. https://doi.org/10.1210/en.2013-1934

Johnson, A. M., Cunningham, C. J., Arnold, E., Rosamond, W. D., & Zègre-Hemsey, J. K. (2021). Impact of using drones in emergency medicine: What does the future hold? Open Access Emergency Medicine, 13, 487–498. https://doi.org/10.2147/OAEM.S247020

Drucker, D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, Article 101351. https://doi.org/10.1016/j.molmet.2021.101351

Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018). Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism, 20(3), 610–619. https://doi.org/10.1111/dom.13120

Ryan, D. H., Lingvay, I., Colhoun, H. M., et al. (2020). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. American Heart Journal, 229, 61–69. https://doi.org/10.1016/j.ahj.2020.07.008

Aroda, V. R., Ahmann, A., Cariou, B., et al. (2019). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials. Diabetes & Metabolism, 45(5), 409–418. https://doi.org/10.1016/j.diabet.2018.12.00

Novo Nordisk. (2021, November 11). Wegovy recommended for approval for the treatment of obesity by the European regulatory authorities (Company announcement No. 72/2021).

U.S. Food and Drug Administration. (n.d.). FDA approves new drug treatment for chronic weight management, first since 2014. Accessed February 20, 2023.

Squadrito, F., Rottura, M., Irrera, N., et al. (2020). Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude. Biomedicine & Pharmacotherapy, 128, Article 110320. https://doi.org/10.1016/j.biopha.2020.110320

Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361

Son, J. W., & Kim, S. (2020). Comprehensive review of current and upcoming anti-obesity drugs. Diabetes & Metabolism Journal, 44(6), 802–818. https://doi.org/10.4093/dmj.2020.0258

Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6

Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022). Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: A systematic review. Clinical Epidemiology, 14, 1463–1476. https://doi.org/10.2147/CLEP.S391819

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review. Pharmaceutical Research, 39(6), 1233–1248. https://doi.org/10.1007/s11095-022-03302-1

Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, Article 645563. https://doi.org/10.3389/fendo.2021.645563

Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023). A narrative review of approved and emerging anti-obesity medications. Saudi Pharmaceutical Journal, 31(10), Article 101757. https://doi.org/10.1016/j.jsps.2023.101757

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

Lautenbach, A., Wernecke, M., Huber, T. B., et al. (2022). The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery: A retrospective analysis. Obesity Surgery, 32(10), 3280–3288. https://doi.org/10.1007/s11695-022-06211-9

Jensen, A. B., Renström, F., Aczél, S., et al. (2023). Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: A retrospective observational study. Obesity Surgery, 33(4), 1017–1025. https://doi.org/10.1007/s11695-023-06484-8

Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: A randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736–1748. https://doi.org/10.1016/S0140-6736(21)00845-X